VSTM stock news · Verastem, Inc.
Get alerts for VSTM
Follow Verastem, Inc. (VSTM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VSTMVerastem announced that CEO Daniel W. Paterson is retiring and Michael Bailey will take over on January 1, 2027.
NeutralVerastem filed details of Michael Bailey's CEO appointment for January 1, 2027, and a $40,000 monthly fee for transition advice. The filing does not change the business outlook.
Verastem, Inc.: Other Events (VSTM)
NeutralVerastem expects to receive about $234.7 million after costs from selling shares and warrants. The cash helps fund the company, but the new shares spread ownership more thinly, leaving the outlook unchanged in this filing.
Verastem, Inc. shares how they did financially and their business situation.
Good for VSTMVerastem estimated that quarterly product sales more than doubled and cash grew from a year earlier. Those figures support a brighter outlook despite an upcoming CEO handover.
Verastem Oncology shares details from its earnings call for the second quarter of 2026.
Good for VSTMVerastem reported a sales rebound, new cash and progress in cancer studies. These updates support a more favorable outlook, though its funding and self-funding plans are not fully complete.